GF Fund Management’s Phathom Pharmaceuticals PHAT Stock Holding History

GF Fund Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.1K	Buy	1,669 +81	+5%	+$924	﹤0.01%	492
2026 Q1	$17.6K	Buy	1,588 +191	+14%	+$2.41K	﹤0.01%	513
2025 Q4	$23.2K	Sell	1,397 -129	-8%	-$1.84K	﹤0.01%	490
2025 Q3	$18K	Sell	1,526 -225	-13%	-$2.32K	﹤0.01%	503
2025 Q2	$16.8K	Hold	1,751	–	–	﹤0.01%	518
2025 Q1	$11K	Buy	1,751 +315	+22%	+$1.91K	﹤0.01%	556
2024 Q4	$11.7K	Buy	+1,436	New	+$17.8K	﹤0.01%	523

Other funds holding PHAT

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

GF Fund Management's PHAT Position: Q2 2026 in Review

GF Fund Management increased its Phathom Pharmaceuticals (PHAT) stake by 5.1% in Q2 2026, buying an estimated $924 and bringing the position to 1,669 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #492.

GF Fund Management first reported a position in PHAT in Q4 2024 and has held it in 7 quarters since. The position peaked at $23.2K in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

GF Fund Management held 1,669 shares of Phathom Pharmaceuticals worth $18.1K as of Q2 2026.
GF Fund Management bought 81 Phathom Pharmaceuticals shares in Q2 2026, an estimated $924.
Phathom Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #492 holding.
GF Fund Management first reported a position in Phathom Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
GF Fund Management's Phathom Pharmaceuticals position peaked at $23.2K in Q4 2025.
161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.